NRO Neurones SA

NEURONES: Description of the share buyback program - Effective implementation

NEURONES: Description of the share buyback program - Effective implementation

INFORMATION

Nanterre, March 16, 2020 (after the closing of the stock exchange)

DESCRIPTION OF THE SHARE BUYBACK PROGRAM

EFFECTIVE IMPLEMENTATION

The Combined Shareholders’ Meeting held on June 6, 2019 renewed the authorization granted to the Board of Directors, for a period of 18 months, to purchase or cause to be purchased the company's own shares.

Pursuant to Articles 241-1 et seq. of the General Regulation of the Autorité des Marchés Financiers, and pursuant to Commission Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No. 596/2014 with regard to regulatory technical standards for the conditions applicable to buyback programs and AMF-approved market practices, this description sets out the objectives and the terms and conditions of the buyback program under which NEURONES (henceforth "the Company") will buy back its own shares, along with the conditions for its effective implementation laid down by the Board of Directors.

1.    Breakdown by objective of the securities held

On February 28, 2020, the number of shares held directly or indirectly by the Company stood at 9,422, representing less than 0.04% of the total capital of 24,285,862 shares.

These shares are held for the purposes of supporting the market for the Company's shares under the liquidity agreement concluded with CIC on August 1, 2019.

  1. Description of the share buyback program authorized by the Shareholders’ Meeting
  • Authorization of the program: sixteenth resolution of the Combined Shareholders' Meeting of June 6, 2019
  • Shares concerned: NEURONES common shares (ISIN Code: FR0004050250)
  • Maximum share of the capital approved by the Shareholders' Meeting for buyback: 10% of the Company's capital (i.e. 2,428,586 shares to date). However, by law, the number of shares acquired with a view to subsequently offering them for exchange or payment during external growth operations may not exceed 5% of the share capital.
  • Maximum purchase price: 30 euros (excluding acquisition costs) per share. However, it should be noted that the maximum purchase price will be adjusted, if need be, should the company undertake financial operations or make decisions affecting the share capital.
  • Maximum value of the program authorized by the Shareholders' Meeting: 72,857,580 euros
  • Program objectives authorized by the Shareholders' Meeting:

The Shareholders' Meeting, ruling pursuant to the provisions of Article L.225-209 of the French Commercial Code, after having reviewed the management report, authorizes the Board of Directors, for a period not exceeding 18 months from this Meeting, to purchase the Company's own shares in order to:

1) subsequently cancel them;

2) cover:

  • a. stock option plans and other forms of share allocation to employees and/or to Group officers, in particular for Company profit sharing, a Company Savings Plan (CSP) or the allocation of free shares;
  • b. financial securities conferring the right to receive Company shares;

       3) support the share price through an Investment Service Provider via a liquidity agreement pursuant to the code of professional conduct of the Association Française des Marchés Financiers (French Association of Financial Markets);

       4) hold purchased shares for subsequent use as exchange or payment during an acquisition.

       The shares may be purchased by intervening on the market or by purchasing blocks, without any specific limitation on such block acquisitions.

  1. Duration of the authorization to implement the program: 18 months from the Shareholders’ Meeting, i.e. up to December 6, 2020.

     
  2. Effective implementation of the share buyback program authorized by the Shareholders' Meeting

The Company's Board of Directors has decided to implement the share buyback program authorized by the Shareholders' Meeting in order to pursue the following two objectives:

-       Support the market for the Company's shares, in particular to encourage their liquidity, via a liquidity agreement pursuant to a code of professional conduct recognized by the AMF, and concluded with an investment service provider in compliance with AMF-approved market practice.

The Company points out that it allocated the cash sum of 400,000 euros to implementing the liquidity agreement concluded on August 1, 2019 with CIC.

-       Cancel the shares bought back in order to reduce the company's share capital, within the framework of and subject to a current authorization from the Shareholders' Meeting

The Board points out that the maximum number of shares that can be acquired for this purpose has been set at 2,000,000, at a maximum price of 21 euros per share (excluding acquisition costs), which represents a maximum total of 42 million euros (excluding costs). This implementation will be effective once this description has been circulated.

About NEURONES

With 5,400 experts, the NEURONES Group specializes in Consulting (Management, Organization and Digital) and IT Services. It supports its clients in their digital transformation projects and in the upgrading of their Information Systems.

Euronext Paris (compartment B - NRO) - Enternext Tech 40 – SRD medium values

Investor Relations:

NEURONES

Paul-César Bonnel

Tel.: +33 (0)1 41 37 41 37

Attachment

EN
18/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neurones SA

 PRESS RELEASE

NEURONES: Organic growth up 5.3% in 2nd quarter 2025

NEURONES: Organic growth up 5.3% in 2nd quarter 2025 PRESS INFORMATION        Nanterre, August 6, 2025 (after trading)Heading: 1st half 2025 revenues Organic growth up 5.3% in 2nd quarter 2025 Revenues (millions of euros)20242025Growthof which organicQ1204.9214.1+ 4.5%+ 3.9%Q2197.5210.2+ 6.4%+ 5.3%Total H1 revenues402.4424.3+ 5.4%+ 4.6% Achievements Organic growth of 5.3% in the second quarter was achieved in a more challenging economic environment. The most notable growth was in Data, Digital projects, market finance, ITSM (Service Now) solutions, and Business Process Management, with t...

 PRESS RELEASE

NEURONES : + 5,3% de croissance organique au 2e trimestre 2025

NEURONES : + 5,3% de croissance organique au 2e trimestre 2025 INFORMATION PRESSE        Nanterre, le 6 août 2025 (après Bourse)Rubrique : C.A. 1er semestre 2025 + 5,3% de croissance organique au 2e trimestre 2025 C.A. (en millions d’euros)20242025Croissancedont organique1er trimestre204,9214,1+ 4,5%+ 3,9%2e trimestre197,5210,2+ 6,4%+ 5,3%Total 1er semestre402,4424,3+ 5,4%+ 4,6% Réalisations A 5,3%, la croissance organique du deuxième trimestre a été réalisée dans des conditions économiques plus tendues. Les progressions les plus notables concernent la Data, les projets Digitaux, la fina...

 PRESS RELEASE

NEURONES : Descriptif du programme de rachat d'actions

NEURONES : Descriptif du programme de rachat d'actions INFORMATION PRESSERubrique : Rachat d’actions                                         Nanterre, le jeudi 5 juin 2025 (après Bourse) DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS L’Assemblée Générale des actionnaires du 5 juin 2025 a renouvelé l’autorisation consentie au Conseil d’administration, pour une durée de 18 mois, de procéder à l’achat des propres actions de la société. Etabli en application de l’article 241-2 et suivants du Règlement général de l’AMF, le présent descriptif précise les modalités et les objectifs du programme d...

 PRESS RELEASE

NEURONES: 3.9% increase in organic growth in the 1st quarter of 2025

NEURONES: 3.9% increase in organic growth in the 1st quarter of 2025 PRESS INFORMATIONHeading: 1st quarter revenues 2025        Nanterre, May 7, 2025 (after trading) 3.9% increase in organic growth in the 1st quarter of 2025 (in millions of euros)Q1 2024Q1 2025Growthof which organicRevenues204.9214.1+ 4.5%+ 3.9% Achievements Driven by its cloud, digital and data activities, the Group's organic growth increased by 3.9% over the first three months of the year. Operating profit (*) totaled 8.2% of revenues. The increase in taxation (the fixed social security charge on bonus shares rose...

 PRESS RELEASE

NEURONES : + 3,9% de croissance organique au 1er trimestre 2025

NEURONES : + 3,9% de croissance organique au 1er trimestre 2025 INFORMATION PRESSERubrique : C.A. 1er trimestre 2025        Nanterre, le 7 mai 2025 (après Bourse) + 3,9% de croissance organique au 1er trimestre 2025 (en millions d’euros)T1 2024T1 2025Croissancedont organiqueChiffre d’affaires204,9214,1+ 4,5%+ 3,9% Réalisations Soutenue par le cloud, le digital et la data, la croissance organique du groupe s’établit à + 3,9% sur les trois premiers mois de l’année. Le résultat opérationnel (*) s’élève à 8,2% du chiffre d’affaires. La fiscalité en hausse (passage de 20 à 30% du forfait soci...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch